351 related articles for article (PubMed ID: 36230543)
21. Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials.
Nambiar DK; Mishra D; Singh RP
Oncol Res; 2023; 31(4):405-421. PubMed ID: 37415740
[TBL] [Abstract][Full Text] [Related]
22. Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs.
Ferretti S; Mercinelli C; Marandino L; Litterio G; Marchioni M; Schips L
Res Rep Urol; 2023; 15():243-259. PubMed ID: 37396015
[TBL] [Abstract][Full Text] [Related]
23. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
24. BRCA2 mutation in advanced lung squamous cell carcinoma treated with Olaparib and a PD-1 inhibitor: a case report.
Chen Z; Wang K; Zhao L; Gong L
Front Oncol; 2023; 13():1190100. PubMed ID: 37260982
[TBL] [Abstract][Full Text] [Related]
25. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
Ray-Coquard I; Leary A; Pignata S; Cropet C; González-Martín A; Marth C; Nagao S; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alia EM; Bogner G; Yoshida H; Lefeuvre-Plesse C; Buderath P; Mosconi AM; Lortholary A; Burges A; Medioni J; El-Balat A; Rodrigues M; Park-Simon TW; Dubot C; Denschlag D; You B; Pujade-Lauraine E; Harter P;
Ann Oncol; 2023 Aug; 34(8):681-692. PubMed ID: 37211045
[TBL] [Abstract][Full Text] [Related]
26. Emerging strategies for cancer therapy by ATR inhibitors.
Yano K; Shiotani B
Cancer Sci; 2023 Jul; 114(7):2709-2721. PubMed ID: 37189251
[TBL] [Abstract][Full Text] [Related]
27. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
Veneziani AC; Scott C; Wakefield MJ; Tinker AV; Lheureux S
Ther Adv Med Oncol; 2023; 15():17588359231157644. PubMed ID: 36872947
[TBL] [Abstract][Full Text] [Related]
28. Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database.
Jesus M; Cabral A; Monteiro C; Duarte AP; Morgado M
Curr Oncol; 2023 Jul; 30(7):6533-6545. PubMed ID: 37504339
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.
Wong WW; O'Brien-Gortner SF; Anderson RF; Wilson WR; Hay MP; Dickson BD
RSC Med Chem; 2023 Jul; 14(7):1309-1330. PubMed ID: 37484567
[TBL] [Abstract][Full Text] [Related]
30. A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
Thavaneswaran S; Kansara M; Lin F; Espinoza D; Grady JP; Lee CK; Ballinger ML; Sebastian L; Corpuz T; Qiu MR; Mundra P; Bailey CG; Schmitz U; Simes J; Joshua AM; Thomas DM
Br J Cancer; 2023 Aug; 129(3):475-485. PubMed ID: 37365284
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Colorectal Cancer Patient with Microsatellite Stability and Germline BRAC2 Mutation Shows a Complete Response to Olaparib in Combination with a PD-1 Inhibitor and Bevacizumab: A Case Report and Review of the Literature.
Song M; Zeng X; Wu Q; Huang J; Dong J; Shao L; Sun Z; Lin Y; Chen S
Life (Basel); 2023 May; 13(5):. PubMed ID: 37240828
[TBL] [Abstract][Full Text] [Related]
32. The role of PARP inhibitor combination therapy in ovarian cancer.
Hockings H; Miller RE
Ther Adv Med Oncol; 2023; 15():17588359231173183. PubMed ID: 37215065
[TBL] [Abstract][Full Text] [Related]
33. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract][Full Text] [Related]
34. Whole-Body Composition Features by Computed Tomography in Ovarian Cancer: Pilot Data on Survival Correlations.
Raia G; Del Grande M; Colombo I; Nerone M; Manganaro L; Gasparri ML; Papadia A; Del Grande F; Rizzo S
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174067
[TBL] [Abstract][Full Text] [Related]
35. Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?
Li Y; Wang X; Hou X; Ma X
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109350
[TBL] [Abstract][Full Text] [Related]
36. Targeting the
Ragupathi A; Singh M; Perez AM; Zhang D
Front Cell Dev Biol; 2023; 11():1133472. PubMed ID: 37035242
[TBL] [Abstract][Full Text] [Related]
37. Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.
Huang X; Li XY; Shan WL; Chen Y; Zhu Q; Xia BR
Front Pharmacol; 2023; 14():1131342. PubMed ID: 37033645
[TBL] [Abstract][Full Text] [Related]
38. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S; Oza A; Hall G; Pardo B; Madry R; Cibula D; Klat J; Montes A; Glasspool R; Colombo N; Pete I; Herrero Ibáñez A; Marín MR; Ilieva R; Timcheva C; Di Maio M; Blakeley C; Taylor R; Barnicle A; Clamp A
Gynecol Oncol; 2023 May; 172():121-129. PubMed ID: 37030280
[TBL] [Abstract][Full Text] [Related]
39. Advances in PARP Inhibitors for Prostate Cancer.
Tisseverasinghe S; Bahoric B; Anidjar M; Probst S; Niazi T
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980735
[TBL] [Abstract][Full Text] [Related]
40. BRCA Mutations-The Achilles Heel of Breast, Ovarian and Other Epithelial Cancers.
Loboda AP; Adonin LS; Zvereva SD; Guschin DY; Korneenko TV; Telegina AV; Kondratieva OK; Frolova SE; Pestov NB; Barlev NA
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
